BHC - Bausch Health Companies - Stock & Dividends

Bausch Health Companies Inc. is a global leader in the development, manufacturing, and marketing of a wide range of specialty pharmaceutical and medical device products. The company's diverse portfolio spans multiple therapeutic areas, including gastroenterology, hepatology, neurology, dermatology, and eye health, as well as aesthetic medical devices and over-the-counter (OTC) products.

The company operates through five distinct segments, each focused on specific product categories and geographic markets. The Salix segment specializes in gastroenterology products for the US market, while the International segment exports a broad range of products, including aesthetic medical devices, branded and generic pharmaceuticals, and OTC products, to countries around the world.

The Solta Medical segment is dedicated to the development and sale of innovative aesthetic medical devices, which are used in various medical and cosmetic procedures. The Diversified segment, meanwhile, offers a diverse range of pharmaceutical products in the US, including neurology and other therapeutic areas, as well as generic products, ortho dermatologic, and dentistry products.

The Bausch + Lomb segment is a global leader in eye health, offering a comprehensive range of products, including vision care, surgical, and ophthalmic pharmaceuticals. This segment is built on a rich legacy of innovation and quality, with a strong commitment to improving eye health and enhancing patient outcomes.

Formerly known as Valeant Pharmaceuticals International, Inc., the company rebranded as Bausch Health Companies Inc. in July 2018, reflecting its renewed focus on innovation, quality, and customer-centricity. Headquartered in Laval, Canada, Bausch Health Companies Inc. is a global company with a strong presence in the US and international markets.